Ignite Creation Date:
2024-05-06 @ 7:26 AM
Last Modification Date:
2024-10-26 @ 11:48 AM
Study NCT ID:
NCT02530476
Status:
COMPLETED
Last Update Posted:
2020-03-31
First Post:
2015-08-19
Brief Title:
Phase III Study of Selective Inhibitor of Nuclear Export SINE Selinexor KPT-330 Sorafenib in Acute Myeloid Leukemia
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Acute Myeloid Leukemia |
| Leukemia |
Keywords:
| Name | View |
|---|---|
| FLT3-inhibitor therapy | View |
| Leukemia | View |
| Acute myeloid leukemia | View |
| AML | View |
| RelapsedRefractory | View |
| FLT3-ITD mutation | View |
| FLT3-mutated high-risk myelodysplastic syndrome | View |
| MDS | View |
| Chronic Myelomonocytic Leukemia | View |
| CMML | View |
| Selinexor | View |
| KPT-330 | View |
| Sorafenib | View |
| Nexavar | View |
| BAY 43-9006 | View |